This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Resilience and Reinvention: Biotech’s Year of Maturity
From capital scarcity to clinical impact, execution and partnerships are redefining the industry’s next chapter.
